

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Use of a A method for increasing the number of islets of Langerhans cells, treatment of prediabetes, treatment or prevention of insulin-dependent diabetes, prevention of non-insulin-dependent diabetes, or treatment of early non-insulin-dependent diabetes, comprising administering to a patient in need thereof an effective amount of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament for increasing the number of islets of Langerhans cells.~~
2. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor A method according to Claim 1, wherein in increasing the number of islets of Langerhans cells, the patient is in need of in the context of the treatment and/or or prevention of diabetes, its complications and/or its or a complication thereof or a related pathologies pathology thereof.~~
3. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the treatment of prediabetes.~~
4. (Currently Amended) ~~Use A method according to Claim 3, for which the wherein said prediabetes is an insulin-dependent prediabetes.~~
5. (Currently Amended) ~~Use A method according to Claim 3, for which the wherein said prediabetes is a non-insulin-dependent prediabetes.~~
6. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament for the A method according to claim 1, which is for the treatment and/or or prevention of insulin-dependent diabetes.~~
7. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the prevention of non-insulin-dependent diabetes.~~

8. (Currently Amended) Use of a kynureine 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the treatment of early non-insulin-dependent diabetes.

9. (Currently Amended) Use A method according to claim 3, for which the said treatment or prevention is by increasing wherein the number of islets of Langerhans cells are increased.

10. (Currently Amended) Use of a kynureine 3-hydroxylase inhibitor in combination with one or more immunosuppressants, for the manufacture of a medicament A method according to claim 1, which is for the prevention and/or or treatment of insulin-dependent diabetes, further comprising administering an immunosuppressant.

11. (Currently Amended) Use A method according to claim 1, which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient with has an impairment in the number of islets of Langerhans cells.

12. (Currently Amended) Use A method according to Claim 11, for which the wherein said patient shows a decrease in the number of islets of Langerhans cells of at least 40%.

13. (Currently Amended) Use A method according to Claim 11, for which the wherein said patient shows a decrease in the number of islets of Langerhans cells of between 50% and to 90%.

14. (Currently Amended) Use A method according to claim 1, wherein the which is suitable for the said treatment and/or the said prevention in the case of a patient with has glucose intolerance.

15. (Currently Amended) Use A method according to Claim 14, for which the wherein said patient presents a fasting glycaemia of between 1.10 g/l and to 1.26 g/l and a glycaemia after meals a meal of between 1.40 g/l and to 2 g/l-after meals.

16. (Currently Amended) Use A method according to claim 1, which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient with has one or more anti-islets of Langerhans cells immunological markers.

17. (Currently Amended) Use A method according to Claim 16, ~~for which the wherein~~ said marker(s) indicate(s) the existence of an autoimmune response of the body directed against the antigenic markers of the body's islets of Langerhans cells.

18. (Currently Amended) Use A method according to Claim 16, ~~for which the wherein~~ said marker(s) is (are) ~~chosen from~~ the anti-islet (ICA), anti-glutamic acid decarboxylase (GAD), anti-tyrosine phosphatase (IA-2) ~~and~~ or anti-(pro)insulin (AIA) auto-antibodies, or the anti-carboxypeptidase H, anti-64kD ~~and~~ or anti-heat shock protein antibodies.

19. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has insulin resistance.

20. (Currently Amended) Use A method according to Claim 19, ~~for which the wherein~~ said patient responds partially or not at all to insulin secreted by the beta cells or injected.

21. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said patient presents a level of glycated haemoglobin of higher than 7%.

22. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said patient has islets of Langerhans cells showing an anomaly of insulin secretion in response to glucose.

23. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said patient presents a suppression of the early peak of insulin secretion.

24. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said patient shows related hyperglycaemia and obesity.

25. (Currently Amended) Use A method according to Claim 24, ~~for which the wherein~~ said patient suffers from paediatric obesity.

26. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient presenting any has a~~ diabetic risk factor.


27. (Currently Amended) Use A method according to Claim 25, ~~for which the wherein~~ said risk factor is ~~chosen from~~ familial history, gestational diabetes, excess weight, obesity, insufficient physical exercise, high blood pressure, a high level of triglycerides, hyperlipidaemia and or inflammation.

28. (Currently Amended) Use A method according to claim 1, comprising the in vitro treatment of isolated islets of Langerhans cells with ~~the~~ said kynurenone 3-hydroxylase inhibitor.


29. (Currently Amended) ~~Process~~ A process for increasing the number or the insulin-secreting capacity of islets of Langerhans cells, comprising the in vitro application of a kynurenone 3-hydroxylase inhibitor to ~~the~~ said cells.

30-32. (Cancelled)

33. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said kynurenone 3-hydroxylase inhibitor is a compound of the general formula (I) or (II):




(I)




(II)

in which:

- W represents a divalent radical ~~chosen from the following radicals:~~





- R^1 represents a ~~radical chosen from~~ linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and or an~~ optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, a heterocyclic radical, an aryl radical ~~and or~~ a heteroaryl radical;
- R^2 is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxy carbonyl, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;
- R^3 is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;
- R^2 and R^3 together also possibly forming a group ~~optionally form~~ $=CR^{16}R^{17}$; or alternatively together ~~forming form~~, with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;
- R^4 is ~~chosen from~~ hydroxyl, alkoxy, alkenyloxy, alkynyoxy, aryloxy, heteroaryloxy, $-N(R^{12}R^{12'})$, $-N(R^{12})OR^{13}$, linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and or an~~ optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl ~~and or~~ a heterocyclic radical;
- R^5 , R^6 , R^7 and R^8 , which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, ~~and or~~ a nitro, cyano, hydroxyl, trifluoromethyl, alkyl, alkoxy, cycloalkyl or aryl radical;
 - the radicals R^5 and R^6 , ~~on the one hand~~, or R^6 and R^7 , ~~on the other hand~~, may also form, together with the carbon atoms to which they are attached, a benzene ring optionally substituted by one or more groups, which may be identical or different, ~~chosen from and are~~ a halogen atom, a trifluoromethyl, cyano or nitro radical, an alkyl radical ~~and or~~ an alkoxy radical;
 - R^9 represents hydrogen or an alkyl radical;
 - R^{10} is ~~chosen from~~ an alkyl, an aryl ~~and or~~ a heteroaryl radical;
 - R^{12} and $R^{12'}$, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen ~~and or~~ an alkyl, alkenyl, alkynyl, alkylcarbonyl, aryl or heteroaryl radical; or alternatively R^{12} and $R^{12'}$ may form, together with the nitrogen atom to which they are attached, a monocyclic or bicyclic heterocyclic group containing a total of 5 to 10 atoms, among which 1, 2, 3 or 4 are ~~chosen~~, independently of each other, ~~from~~ nitrogen, oxygen ~~and or~~ sulfur,

the said heterocyclic radical also optionally comprising 1, 2, 3 or 4 double bonds and optionally being substituted by one or more ~~chemical~~ groups, which may be identical or different, ~~chosen from and are~~ hydroxyl, halogen atom, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclic radical and or trifluoromethyl;

- R¹³ is ~~chosen from~~ hydrogen and or an alkyl, alkenyl, alkynyl, aryl, heteroaryl, -N(R¹²R¹²) or -N(R¹²)OR¹³ radical;

- R¹⁴ is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxy carbonyl, aryl, arylalkyl, heteroaryl, cycloalkyl and or a heterocyclic radical;

- R¹⁴ may also form a bond with R², thus forming a double bond between the carbon atoms respectively bearing the substituents R¹⁴ and R²; or alternatively R¹⁴ forms, with R² and with the carbon atoms that bear them, a ring containing a total of 3, 4, 5, 6 or 7 carbon atoms, among which 1, 2 or 3 may be replaced with ~~an atom chosen from~~ nitrogen, oxygen and or sulfur, the said ring possibly optionally comprising one or more unsaturations in the form of (a) double bond(s), and being optionally substituted by one or more radicals, which may be identical or different, ~~chosen from and are~~ oxo, alkoxy, alkoxy carbonyl and or alkylcarbonyloxy;

- R¹⁵ is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkoxy carbonyl, alkoxy, alkenyloxy, alkynyoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclthio, aryl, heteroaryl, cycloalkyl and or a heterocyclic radical;

- R¹⁴ and R¹⁵ also possibly forming optionally form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

- R¹⁶ and R¹⁷, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, an alkyl, aryl, heteroaryl or cycloalkyl radical and or a heterocyclic radical; or alternatively

- R¹⁶ and R¹⁷ form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical; and

- R¹¹ is ~~chosen from~~ hydrogen and or an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl radical, and any or a protecting group for an amine function;

~~and also the possible~~ or a geometrical and/or or optical isomers isomer thereof, ~~and possi-~~

~~ble or a tautomeric forms form~~ thereof;

~~the solvates and hydrates of these compounds; or a solvate or hydrate thereof; or a
and also the possible salts salt~~ thereof with a pharmaceutically acceptable acid or base, or
~~alternatively the a pharmaceutically acceptable prodrugs of these compounds prodrug~~ thereof.

34-54. (Cancelled)

55. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase.

56. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase in an *in vitro* test.